Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084907 | 0.96 | F10 (0.64) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8098336 | 0.95 | F10 (0.63) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2192401 | 0.95 | F10 (0.63) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2189599 | 0.94 | F10 (0.63) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL8102794 | 0.94 | F10 (0.63) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2191039 | 0.94 | F10 (0.62) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3075487 | 0.94 | F10 (0.63) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2218726 | 0.93 | F10 (0.67) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2218721 | 0.93 | F10 (0.67) | F10CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL12415551 | 0.93 | F10 (0.65) | F10CYP3A4CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | F10 126/4885CYP3A4 145/4885CYP2C9 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.